ArticleCureus2025
A Prospective Evaluation of Tocilizumab in Patients With Rheumatoid Arthritis Refractory to Conventional Disease-Modifying Anti-Rheumatic Medications (DMARDs).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic medications (DMARDs) remains a therapeutic challenge, necessitating the use of biologic agents such as tocilizumab.
objectiveTo prospectively evaluate the efficacy of tocilizumab in reducing disease activity, measured by DAS28 (ESR), and to assess its safety in terms of adverse events over a six-month follow-up in a real-world South Asian cohort. METHODOLOGY: This prospective observational study was conducted at the Department of Rheumatology, Abbas Institute of Medical Sciences, Muzaffarabad, over a two-year period (June 2022-May 2024). A total of 192 patients meeting the 2010 ACR/EULAR RA criteria, with inadequate response to at least two csDMARDs, including methotrexate and a baseline DAS28 (ESR) ≥5.1, were enrolled. Tocilizumab (4-8 mg/kg) was administered intravenously every four weeks for six months. DAS28 scores were recorded at baseline, 12 weeks, and 24 weeks. Safety was assessed through serial laboratory monitoring and systematic documentation of adverse events.
resultsOf the 192 patients (77.08% female; mean age 44 ± 10.6 years), the mean DAS28 score decreased from 5.91 ± 0.42 at baseline to 3.76 ± 0.59 at 12 weeks and 2.43 ± 0.71 at 24 weeks (p < 0.001). Remission (DAS28 ≤ 2.6) was achieved in 112 patients (58.33%), while 58 (30.21%) showed partial response and 22 (11.46%) had no response. Adverse events were reported in 52 patients (27.08%), most commonly infections, lipid abnormalities, and gastritis.
conclusionTocilizumab is a highly effective and generally well-tolerated treatment option for RA patients unresponsive to csDMARDs, though longer follow-up and controlled comparisons are needed to confirm long-term safety and causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.